loading
前日終値:
$298.50
開ける:
$297.67
24時間の取引高:
164.50K
Relative Volume:
0.73
時価総額:
$5.89B
収益:
$274.48M
当期純損益:
$153.56M
株価収益率:
40.07
EPS:
7.3755
ネットキャッシュフロー:
$114.06M
1週間 パフォーマンス:
-2.08%
1か月 パフォーマンス:
+7.39%
6か月 パフォーマンス:
+32.39%
1年 パフォーマンス:
+63.49%
1日の値動き範囲:
Value
$292.56
$297.67
1週間の範囲:
Value
$292.28
$311.86
52週間の値動き範囲:
Value
$175.89
$326.63

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name
名前
Ligand Pharmaceuticals Inc
Name
セクター
Healthcare (1052)
Name
電話
858-550-7500
Name
住所
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Name
職員
47
Name
Twitter
@Ligand_LGND
Name
次回の収益日
2026-10-29
Name
最新のSEC提出書
Name
LGND's Discussions on Twitter

Compare LGND vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
LGND icon
LGND
Ligand Pharmaceuticals Inc
295.54 5.89B 274.48M 153.56M 114.06M 7.3755
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-25 開始されました Barclays Overweight
2026-08-14 開始されました Leerink Partners Outperform
2026-07-21 再開されました Citigroup Buy
2026-03-11 開始されました BofA Securities Buy
2025-12-09 開始されました Citigroup Buy
2025-04-10 開始されました Stifel Buy
2024-10-03 開始されました Oppenheimer Outperform
2024-07-30 開始されました RBC Capital Mkts Outperform
2021-04-14 再開されました Stephens Overweight
2021-02-04 繰り返されました H.C. Wainwright Buy
2020-10-06 開始されました Barclays Overweight
2020-03-24 ダウングレード Argus Buy → Hold
2020-03-10 開始されました Guggenheim Neutral
2020-02-06 開始されました The Benchmark Company Buy
2019-09-19 アップグレード Barclays Equal Weight → Overweight
2019-06-11 開始されました Barclays Equal Weight
2019-05-03 繰り返されました H.C. Wainwright Buy
2019-03-06 繰り返されました H.C. Wainwright Buy
2018-10-29 アップグレード ROTH Capital Neutral → Buy
2018-10-02 繰り返されました H.C. Wainwright Buy
2018-09-11 繰り返されました Argus Buy
2018-08-17 開始されました Goldman Neutral
2018-08-08 ダウングレード ROTH Capital Buy → Neutral
2018-06-21 開始されました Argus Buy
2017-12-27 繰り返されました H.C. Wainwright Buy
2017-09-05 再開されました H.C. Wainwright Buy
2016-10-05 繰り返されました H.C. Wainwright Buy
2016-08-05 ダウングレード Deutsche Bank Hold → Sell
2016-03-11 開始されました Sidoti Buy
2016-03-03 開始されました H.C. Wainwright Buy
すべてを表示

Ligand Pharmaceuticals Inc (LGND) 最新ニュース

pulisher
Oct 11, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada

Oct 11, 2026
pulisher
Oct 11, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada

Oct 11, 2026
pulisher
Oct 11, 2026

Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock By Investing.com - Investing.com South Africa

Oct 11, 2026
pulisher
Oct 11, 2026

Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock - Investing.com

Oct 11, 2026
pulisher
Oct 11, 2026

Form 4 Ligand Pharmaceuticals Incorporated For: 11 October By Investing.com - Investing.com Canada

Oct 11, 2026
pulisher
Oct 08, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock forecasts - Yahoo Finance UK

Oct 08, 2026
pulisher
Oct 07, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance

Oct 07, 2026
pulisher
Oct 07, 2026

Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call - Benzinga

Oct 07, 2026
pulisher
Oct 07, 2026

Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call - Benzinga

Oct 07, 2026
pulisher
Oct 02, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada

Oct 02, 2026
pulisher
Oct 01, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance

Oct 01, 2026
pulisher
Sep 29, 2026

Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance

Sep 29, 2026
pulisher
Sep 29, 2026

Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell? - Yahoo Finance

Sep 29, 2026
pulisher
Sep 29, 2026

Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook? - Yahoo Finance

Sep 29, 2026
pulisher
Sep 28, 2026

Form 4 Ligand Pharmaceuticals Incorporated For: 28 September By Investing.com - Investing.com Nigeria

Sep 28, 2026
pulisher
Sep 27, 2026

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones - Yahoo Finance

Sep 27, 2026
pulisher
Sep 25, 2026

Barclays Initiates Outperform on Ligand Pharmaceuticals (LGND) w - GuruFocus

Sep 25, 2026
pulisher
Sep 25, 2026

Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Barclays initiates Ligand Pharma stock with overweight rating - Investing.com

Sep 25, 2026
pulisher
Sep 25, 2026

Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target - Yahoo Finance

Sep 25, 2026
pulisher
Sep 24, 2026

US53220KAJ7 Bond Profile: Coupon and Redemption - TradingView

Sep 24, 2026
pulisher
Sep 24, 2026

Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

Ligand and AvenCell Therapeutics Enter Financing Agreement - GlobeNewswire

Sep 24, 2026
pulisher
Sep 23, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

McDermott Will & Schulte advises Ligand Pharmaceuticals in $23 million acquisition of royalty and milestone interest in Santen’s Ryjunea® - McDermott Will & Schulte

Sep 23, 2026
pulisher
Sep 22, 2026

Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® - Yahoo Finance

Sep 22, 2026
pulisher
Sep 19, 2026

Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold - Seeking Alpha

Sep 19, 2026
pulisher
Sep 10, 2026

A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan

Sep 10, 2026
pulisher
Sep 09, 2026

Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia

Sep 09, 2026
pulisher
Sep 09, 2026

Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia

Sep 09, 2026
pulisher
Sep 08, 2026

Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Canada

Sep 08, 2026
pulisher
Sep 08, 2026

Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st

Sep 08, 2026
pulisher
Sep 08, 2026

Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com South Africa

Sep 08, 2026
pulisher
Sep 08, 2026

Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com UK

Sep 08, 2026
pulisher
Sep 04, 2026

Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com

Sep 04, 2026
pulisher
Sep 04, 2026

ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView

Sep 04, 2026
pulisher
Sep 04, 2026

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance

Sep 04, 2026
pulisher
Sep 03, 2026

Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan

Sep 03, 2026
pulisher
Sep 02, 2026

XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart

Sep 02, 2026
pulisher
Sep 02, 2026

If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga

Sep 02, 2026
pulisher
Sep 02, 2026

A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan

Sep 02, 2026
pulisher
Sep 02, 2026

Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView

Sep 02, 2026
pulisher
Sep 01, 2026

Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView

Sep 01, 2026
pulisher
Aug 26, 2026

Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada

Aug 26, 2026
pulisher
Aug 26, 2026

Ligand to Participate in September Investor Conferences - marketscreener.com

Aug 26, 2026
pulisher
Aug 26, 2026

Ligand executives will meet investors at three September events - Stock Titan

Aug 26, 2026
pulisher
Aug 26, 2026

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital - Yahoo Finance

Aug 26, 2026
pulisher
Aug 24, 2026

Ligand (LGND) Snapshot: Ends Down by 2.13% at $280.18 for the Current Session; Price Setup: the Supplied Trading Band Runs From $266.17 to $294.19 at the CloseEarnings Breakout Stocks - vinanet.vn

Aug 24, 2026

Ligand Pharmaceuticals Inc (LGND) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ligand Pharmaceuticals Inc (LGND) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Reardon Andrew
CLO & Secretary
Oct 02 '26
Sale
304.07
5,000
1,520,346
31,854
Zimmermann Martine
Director
Sep 10 '26
Sale
285.00
1,200
342,000
3,897
MARTINE ZIMMERMANN
Director
Sep 10 '26
Proposed Sale
285.00
1,200
342,000
0
ANDREW REARDON
Officer
Sep 03 '26
Proposed Sale
286.92
15,000
4,303,800
0
Reardon Andrew
CLO & Secretary
Sep 03 '26
Sale
286.09
5,000
1,430,434
36,514
Haas Jason
Director
Aug 12 '26
Sale
292.81
7,138
2,090,062
3,981
Haas Jason
Director
Aug 12 '26
Option Exercise
51.56
6,138
316,475
11,119
Espinoza Octavio
Chief Financial Officer
Aug 12 '26
Option Exercise
56.91
31,641
1,800,574
59,337
OCTAVIO ESPINOZA
Officer
Aug 12 '26
Proposed Sale
288.75
31,641
9,136,339
0
Jason Haas
Director
Aug 12 '26
Proposed Sale
292.81
7,138
2,090,062
0
$86.17
price down icon 2.05%
$142.78
price down icon 6.45%
$13.62
price down icon 7.47%
$26.73
price down icon 2.84%
KOD KOD
$85.75
price down icon 2.69%
$59.85
price down icon 3.25%
大文字化:     |  ボリューム (24 時間):